By Kate Baggaley
ORLANDO, Fla.—Savings over the next five years due to biosimilars are projected to exceed $100 billion in the United States, according to data from IQVIA presented at the NASP 2022 Annual Meeting & Expo.
“There’s plenty of opportunity going forward, both on the small molecules side and on the biological side,” said Doug Long, the vice president of industry relations for the company. The expected launches of biosimilars for adalimumab (Humira,